← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Viewpoint Molecular Targeting, Inc.
Coralville, IA
$13,287,302
Total funding
11
Grants
Funding over time
peak $3M · FY2015–24$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$13,287,302 · 11
By mechanism
R44$9,854,542 · 5
N44$1,944,651 · 1
R43$798,372 · 3
R42$391,553 · 1
N43$298,184 · 1
Investigators at Viewpoint Molecular Targeting, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
"Systemic Targeted Radionuclide Therapy for Metastatic Melanoma"Period of Performance: 9/18/2017 - 9/17/2019$1,944,651
N44 · FY2017 · CA
Phase 1 cross over biodistribution study of [203Pb]VMT01 for single photon emission computed tomography (SPECT) and [68Ga]VMT02 for positron emission tomography (PET) imaging of stage 4 melanoma$1,023,920
R44 · FY2020 · CA
GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for Pb-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma.$999,883
R44 · FY2020 · CA
GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for Pb-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma.$999,883
R44 · FY2021 · CA
Preclinical pharmacology, toxicology, biodistribution and dosimetry, and radionuclide production CMC validation for Pb-212 receptor targeted alpha-particle therapy for neuroendocrine tumors.$998,648
R44 · FY2021 · CA
Preclinical pharmacology, toxicology, biodistribution and dosimetry, and radionuclide production CMC validation for Pb-212 receptor targeted alpha-particle therapy for neuroendocrine tumors.$997,658
R44 · FY2020 · CA
Image-guided dosimetry-based alpha particle therapy for neuroblastoma.$990,225
R44 · FY2022 · CA
Combining receptor-targeted alpha particle therapy and immunotherapy to achieve complete responses in metastatic melanoma$976,668
R44 · FY2022 · CA
Image-guided dosimetry-based alpha particle therapy for neuroblastoma.$961,450
R44 · FY2023 · CA
Phase 1 cross over biodistribution study of [203Pb]VMT01 for single photon emission computed tomography (SPECT) and [68Ga]VMT02 for positron emission tomography (PET) imaging of stage 4 melanoma$958,108
R44 · FY2019 · CA
Combining receptor-targeted alpha particle therapy and immunotherapy to achieve complete responses in metastatic melanoma$948,099
R44 · FY2023 · CA
Antibody-based prertargeted alpha particle therapy for ovarian cancer$391,553
R42 · FY2024 · CA
Receptor-targeted radionuclide therapy combined with immunotherapies to improve metastatic melanoma tumor response.$300,000
R43 · FY2019 · CA
Production of Image-Guided Metastatic Melanoma Therapy Radiopharmaceuticals$298,530
R43 · FY2016 · CA
SBIR PHASE I-RADIONUCLIDE THERAPY FOR METASTATIC MELANOMA VIEWPOINT MOLECULAR TARGETING, LLC:1256544 [15-068338] IGF::OT::IGF$298,184
N43 · FY2015 · CA
Image guided therapy for metastatic melanoma$149,842
R43 · FY2015 · CA
Production of Image-Guided Metastatic Melanoma Therapy Radiopharmaceuticals$50,000
R43 · FY2017 · CA